uniQure N.V. Earnings Per Share (Diluted)
uniQure N.V. (QURE) reported Earnings Per Share (Diluted) of -$0.85 per share for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-05-05
- uniQure N.V. earnings per share, diluted for the quarter ending 2026-03-31 was -$0.85.
- uniQure N.V. earnings per share, diluted for the quarter ending 2025-12-31 was -$0.60.
- uniQure N.V. earnings per share, diluted for the quarter ending 2025-09-30 was -$1.38.
- uniQure N.V. earnings per share, diluted for the quarter ending 2025-06-30 was -$0.69.
- uniQure N.V. earnings per share, diluted for fiscal 2025 was -$3.46.
- uniQure N.V. earnings per share, diluted for fiscal 2024 was -$4.92.
- uniQure N.V. earnings per share, diluted for fiscal 2023 was -$6.47.
- uniQure N.V. earnings per share, diluted for fiscal 2022 was -$2.71, a 138.49% decline from fiscal 2021.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|
| 2026-03-31 | -$0.85 10-Q · filed 2026-05-05 | -$1.45 derived: net income ÷ weighted average shares · filed 2026-05-05 | -$2.80 derived: net income ÷ weighted average shares · filed 2026-05-05 | -$3.50 derived: net income ÷ weighted average shares · filed 2026-05-05 |
| 2025-12-31 | -$0.60 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$1.95 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$2.65 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$3.46 10-K · filed 2026-03-02 |
| 2025-09-30 | -$1.38 10-Q · filed 2025-11-10 | -$2.09 derived: net income ÷ weighted average shares · filed 2025-11-10 | -$2.90 10-Q · filed 2025-11-10 | -$4.37 derived: net income ÷ weighted average shares · filed 2026-05-05 |
| 2025-06-30 | -$0.69 10-Q · filed 2025-07-29 | -$1.49 10-Q · filed 2025-07-29 | -$2.96 derived: net income ÷ weighted average shares · filed 2026-05-05 | -$3.87 derived: net income ÷ weighted average shares · filed 2026-05-05 |
| 2025-03-31 | -$0.82 10-Q · filed 2026-05-05 | -$2.29 derived: net income ÷ weighted average shares · filed 2026-05-05 | -$3.21 derived: net income ÷ weighted average shares · filed 2026-05-05 | -$4.37 derived: net income ÷ weighted average shares · filed 2026-05-05 |
| 2024-12-31 | -$1.50 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$2.41 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$3.57 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$4.92 10-K · filed 2026-03-02 |
| 2024-09-30 | -$0.91 10-Q · filed 2025-11-10 | -$2.07 derived: net income ÷ weighted average shares · filed 2025-11-10 | -$3.42 10-Q · filed 2025-11-10 | |
| 2024-06-30 | -$1.16 10-Q · filed 2025-07-29 | -$2.51 10-Q · filed 2025-07-29 | ||
| 2024-03-31 | -$1.36 10-Q · filed 2025-05-09 | |||
| 2023-12-31 | -$6.47 10-K · filed 2026-03-02 | |||
| 2023-09-30 | -$1.88 10-Q · filed 2024-11-05 | -$4.94 10-Q · filed 2024-11-05 | ||
| 2023-06-30 | -$1.44 10-Q · filed 2024-08-01 | -$3.06 10-Q · filed 2024-08-01 | ||
| 2023-03-31 | -$1.63 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | -$2.71 10-K · filed 2025-02-27 | |||
| 2022-09-30 | -$1.02 10-Q · filed 2023-11-07 | -$2.86 10-Q · filed 2023-11-07 | ||
| 2022-06-30 | -$0.84 10-Q · filed 2023-08-01 | -$1.84 10-Q · filed 2023-08-01 | ||
| 2022-03-31 | -$1.00 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $7.04 10-K · filed 2024-02-28 | |||
| 2021-09-30 | -$0.79 10-Q · filed 2022-11-02 | $6.87 10-Q · filed 2022-11-02 | ||
| 2021-06-30 | $8.51 10-Q · filed 2022-08-08 | $7.67 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | -$0.91 10-Q · filed 2022-05-02 | |||
| 2020-12-31 | -$2.81 10-K · filed 2023-02-27 | |||
| 2020-09-30 | -$1.21 10-Q · filed 2021-10-25 | -$2.80 10-Q · filed 2021-10-25 | ||
| 2020-06-30 | -$0.96 10-Q · filed 2021-07-26 | -$1.59 10-Q · filed 2021-07-26 | ||
| 2019-12-31 | -$3.11 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |